Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio Approach

MELBOURNE, Australia and INDIANAPOLIS, April 28, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") announces an educational webinar exploring the evolution of PSMA[1]-targeted radionuclide therapy and Telix's differentiated, multi-product approach to treating prostate cancer across the disease... The post Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio Approach appeared first on Kosmo Digital .

Go to News Site